logo
Plus   Neg
Share
Email
Comment

FDA Clears Pluristem's Phase II Clinical Trial In Intermittent Claudication

Pluristem Therapeutics Inc. (PSTI) announced that the United States Food and Drug Administration or FDA has granted the company clearance to start a Phase II clinical trial using the company's PLX-PAD cell product candidate for the treatment of Intermittent Claudication or IC, a subset of peripheral artery disease or PAD.

Pluristem's IC Phase II trial will evaluate the safety and efficacy of two doses (150x106 and 300x106) of PLX-PAD cells versus placebo administered via two intramuscular injections (day one and week twelve post initial injection).

The company noted that the study population will be comprised of 132 patients (44 in each cohort) with IC, Fontaine class IIb; Rutherford category 2-3, in approximately 10 U.S. clinical sites.

The primary efficacy end point of the trial will be the change in the Maximal Walking Distance from baseline during an Exercise Treadmill Test. Secondary endpoints will include hemodynamics and quality of life measurements. Safety parameters will also be assessed.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of BP Plc were losing around 2 percent in the morning trading in London after the British energy giant said Tuesday that it now expects to take a post-tax non-operating charge of around $1.7 billion in its fourth quarter for Deepwater Horizon settlement program. BlackBerry Ltd. has introduced a new a cloud-based cybersecurity program that will scan automakers' software for threats amid increased concerns about hacking in Internet-connected cars. BlackBerry Jarvis, the transformational software cybersecurity product, helps carmakers detect security flaws in software before it goes into their vehicles. General Motors Co. said it plans to mass-produce self driving cars that will have no steering wheel, pedals or manual controls by 2019. The automaker has filed a safety petition with the Department of Transportation for its fourth-generation self-driving Cruise AV, its first production-ready vehicle built from the start to operate safely on its own.
comments powered by Disqus
Follow RTT